Superagonist Technology News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Superagonist Technology. Real-time updates on events, politics, business and more.

SOTIO Biotech: SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with Cetuximab

January 19, 2023

BASEL, Jan. 19, 2023, a clinical stage immuno-oncology company owned by PPF Group, announced today that the first patient was dosed in its Phase 2 AURELIO-05 combination trial of nanrilkefusp alfa

Region Flamande Kostenloser Wertpapierhandel Richard Sachse Karen Geboes Eric Van Cutsem Michael Tattory

Source: finanznachrichten.de

SOTIO Biotech: SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA (pembrolizumab)

July 26, 2022

AURELIO-04 will enroll up to 320 patients and test the combination in multiple solid tumor indicationsClinical collaborator, MSD (Merck & Co., Inc., Rahway, NJ, USA), will supply KEYTRUDA for the study

United States Czech Republic Kostenloser Wertpapierhandel Richard Sachse Michael Tattory Peter Grell

Source: finanznachrichten.de

Investegate |SOTIO Biotech Announcements | SOTIO Biotech: SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)

July 26, 2022

Investegate announcements from SOTIO Biotech, SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)

Czech Republic United States Richard Sachse Michael Tattory Peter Grell Richard Kapsa

Source: investegate.co.uk

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Superagonist Technology News Today

SOTIO Biotech: SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with Cetuximab

SOTIO Biotech: SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA (pembrolizumab)

Investegate |SOTIO Biotech Announcements | SOTIO Biotech: SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA&#xAE; (pembrolizumab)

Explore More Categories

Investegate |SOTIO Biotech Announcements | SOTIO Biotech: SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)